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Abstract Introduction: Recent studies have indicated that
a proportion of patients with renal failure, left ventricular
hypertrophy, or cryptogenic stroke have sequence variants
in their aGal A gene (Fabry disease), which has resulted in
an increase in diagnostic activities for this disorder. The
diagnostic process for lysosomal storage disorders may
result in findings of unknown clinical significance. Here we
report such an unexpected outcome.
Case: A 32-year-old male presented at the emergency
department because of a transient ischemic attack. Exten-
sive investigations revealed no cause and an initial
diagnosis of cryptogenic stroke was made. Subsequently,
aGal A activity was measured in a bloodspot and was
shown to be normal, but the activity of alpha-L-iduronidase
(IDUA), used as reference enzyme, was unexpectedly low:
0.5 umol/L (ref ¼ 1.7–14.3). A diagnosis of IDUA
deficiency, mucopolysaccharidosis type 1S or Scheie
disease was considered. IDUA gene analysis revealed two
homozygous sequence alterations: a silent sequence change
(979C > T) in exon 7 (N297N) and an unknown missense
mutation 875A > T (R263W). Physical examination was
completely normal, without clinical signs of mucopolysac-
charidosis type I (MPS I). Leukocyte IDUA activity was
also low: 2.1 nmol/mg prot/h (ref ¼ 14–40 nmol prot/h),
but higher than the patient range of <0.1 nmol/mg prot/h.
Urinary glycosaminoglycan levels were normal both quan-
titatively and qualitatively. It was concluded that there was
low IDUA activity without clinical symptoms and the
diagnosis of mucopolysaccharidosis I was discarded.
Conclusion: The diagnostic process for lysosomal
storage disorders may result in biochemical abnormalities
of unknown clinical significance. Early evaluation by a
specialist in inborn errors of metabolism may help to avoid
anxiety in patients and unnecessary additional analyses.
Introduction
Fabry disease (FD, MIM 301500) is an X-linked lyso-
somal storage disorder, caused by a deficiency of
a-galactosidase A (alfa-Gal A; EC 3.2.1.22). This results
in the accumulation of its substrates, glycosphingolipids
with an 1,4 galactosyl moiety in various cell types
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throughout the body. This ultimately causes the clinical
presentation that in its typical (also called classical)
phenotype presents with acroparesthesias, anhidrosis, and
angiokeratoma in young male adults. Later in life, an
increase in cardiovascular complications, including renal
failure, occurs in males and to a lesser extent in females
(Zarate and Hopkin 2008). As of 2001, enzyme replace-
ment therapy (ERT) is available, but long-term studies have
shown that ERT has limited efficacy in advanced disease
(Lidove et al. 2010). This observation has resulted in efforts
to increase awareness of Fabry disease. One way to detect
Fabry disease is through aGal A activity analysis in high-
risk populations. Patients identified through this method
may subsequently be treated as Fabry patients, but more
importantly, it may also lead to the identification of hitherto
asymptomatic, yet affected, family members. Indeed, recent
studies have shown that a small proportion of patients with
renal failure, left ventricular hypertrophy or cryptogenic
stroke have sequence variations in the gene encoding alpha-
Galactosidase A (GLA, for review see (Linthorst et al.
2010)). Yet, it is unclear whether all patients with GLA
sequence abnormalities should be considered as Fabry
patients, as the clinical significance of their mutations is
frequently unknown.
Both mutation analysis and the measurement of enzyme
activity are performed in the diagnostic process. In males,
detection of alpha-Galactosidase A deficiency remains the
gold standard of diagnosing the disease (Gal et al. 2011).
Chamoles showed in 2001 that bloodspots may serve as an
alternative for the analysis of lysosomal enzyme activity in
isolated leukocytes or lymphocytes (Chamoles et al. 2001).
To correct for a variable leukocyte count per spot, the
activity of a second lysosomal enzyme is generally used as
reference value.
Here we report on an unusual outcome of the diagnostic
process for Fabry disease.
Case
A 32-year-old Dutch man of non-consanguineous Moroc-
can parents presented in the emergency department with
complaints indicating facial nerve palsy and possible
hypoglossal nerve palsy. These symptoms resolved sponta-
neously within 24 h and it was considered to have been a
transient ischemic attack (TIA). The patient had no risk
factors for cerebrovascular disease. Extensive additional
investigations were performed, but these revealed no cause:
MRI brain, transthoracic and transesophageal echocardiog-
raphy, and 24 h EKG registration were all normal. No
coagulopathy, vasculitis, or carotid dissection was detected.
A diagnosis of cryptogenic stroke was made and diagnos-
tics for Fabry disease were initiated.
Analysis of a bloodspot revealed normal aGal A enzyme
activity. Thus, Fabry disease was ruled out. Unexpectedly,
activity of a-L iduronidase (IDUA; EC 3.2.1.76), which
was used as a reference enzyme, was 0.5 mmol/h/L
(reference range: 1.7–14.3 mmol/h/L). A second sample
was requested, yielding similar results (IDUA activity 0.8
mmol/h/L). It was concluded there was low IDUA activity,
possibly related to mucopolysaccharidosis type I (MPS I,
Scheie phenotype).
Subsequently, a diagnosis of Scheie disease was consid-
ered and genetic analysis was requested. Analysis of the
IDUA gene resulted in the identification of two unknown
homozygous alterations of unknown clinical significance: a
missense mutation c.875A >T (p.R263W) in exon 6, and a
silent mutation, c.979C > T that does not result in an amino
acid sequence alteration (p.N297N) in exon 7. The patient
was told that a diagnosis of MPS I was likely and he was
referred to an expert center in lysosomal storage diseases at
another hospital.
Here, further assessment of the patient’s history revealed
that the patient had been healthy until the TIA, from which
he had recovered completely. He had never experienced
any complaints related to joint mobility, changes in facial
morphology, or reduced exercise tolerance. Family history
was negative for inborn errors of metabolism. Physical
examination was completely normal and he had reached
normal height (180 cm). In particular, there were no
dysmorphic signs, cardiac and pulmonary sounds were
normal and there was no organomegaly. The extremities did
not demonstrate abnormalities and all joints had full range
of motion. There were no signs of corneal clouding.
Additional laboratory evaluations were performed. Glycos-
aminoglycan excretion in urine measured by means of a
dimethylene blue test was normal 5 mg/mmol creatinine
(reference range: 1–8 mg/mmol creatinine). In addition,
two-dimensional electrophoresis of urinary glycosamino-
glycans showed a normal pattern. IDUA activity in
leukocytes was consistent with the results of the bloodspot
assay: 2.1 nmol/mg prot/h (reference range: 14.0–40.0
nmol/mg prot/h ). This is well above the patient range seen
in our center (<0.1 nmol/mg prot/h).
Despite the low IDUA activity, the significant residual
IDUA activity and the clinical presentation were considered
not to be consistent with MPS I. The normal excretion of
GAGs in urine was supportive of this assumption. The
diagnosis of MPS I was discarded.
Discussion
A 32-year-old man was evaluated for Fabry disease because
of a cryptogenic stroke. In bloodspot, no alfa-Gal A
deficiency was found. IDUA was used as a reference
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enzyme and repeatedly turned out to be low. After reference
to a specialized center, this was confirmed in additional
laboratory investigations, but not to such an extent as seen
in mucopolysaccharidosis-I patients. The patient experi-
enced no complaints compatible with MPS-I and there were
no physical signs of the disease. Measurement of the
storage product (glycosaminoglycans in urine) revealed
normal levels.
Deficiency of a-L iduronidase leads to mucopolysacchar-
idosis type I. This disease has a wide phenotypic range and
is often categorized in three subtypes. The severe form,
Hurler syndrome (MPS IH; MIM 607014) presents in
infancy and if left untreated will lead to premature death in
childhood. It is characterized by mental retardation,
hepatosplenomegaly, coarse facial features, corneal cloud-
ing, joint and bone deformities known as “dysostosis
multiplex,” macroglossia, valvular heart disease, obstruc-
tive airway disease, and inguinal or umbilical hernias. The
intermediate phenotype Hurler/Scheie (MPS IH/S; MIM
607015) presents in childhood and has a slower progression
without cognitive impairment. Survival into adulthood is
common. Scheie syndrome (MPS IS; MIM 607016) is the
attenuated form of MPS I and may present in late childhood
or even adolescence. As in Hurler-Scheie, somatic disease
is present without cognitive impairment (Neufeld and
Muenzer 2007).
Although MPS may cause coronary artery insufficiency
and myocardial infarction (Lin et al. 2005), a cerebrovas-
cular event as presenting MPS I symptom has only recently
been described in one individual (Fujii et al. 2012). In this
particular case, the characteristic dysmorphology was the
clue to the ultimate diagnosis of MPS I. The accumulation
of glycosaminoglycans in (cells of) the vascular wall may
induce reduced elasticity and atherosclerotic-like plaques in
animal models and patients (Kelly et al. 2012; Lyons et al.
2011; Wang et al. 2011). These effects, however, are seen
in advanced disease only and never in the absence of other
disease-specific symptoms.In this light, it is very unlikely
that a low IDUA activity may be explanatory for the
cryptogenic stroke in this patient. Despite the reduced
enzyme activity, we could not demonstrate an increase
in GAG excretion in urine. The presence of two
homozygous mutations is remarkable given the reported
non-consanguinity of the patient’s parents.
There are many examples in the literature where
mutations in genes of lysosomal hydrolases may be
accompanied by severely reduced enzymatic activities
in vitro, without correlated clinical symptoms. This has been
shown for Fabry disease (Froissart et al. 2003), Tay-Sachs
disease (Triggs-Raine et al. 1992), Pompe disease (Nishi-
moto et al. 1988), and also in mucopolysaccharidosis type I,
the disease suspected in the present case (Aronovich et al.
1996). These inconsistencies are usually explained by the
fact that the in vitro diagnostic procedure to measure enzyme
activity is performed by means of artificial substrates.
Apparently, some coding region sequence variants may
result in a reduced specificity toward artificial substrates,
but not for natural substrates (Froissart et al. 2003).
Incidental findings such as described here, are a well-
known phenomenon in the current practice of medicine,
especially in radiology and genomics (Couzin-Frankel 2011;
Soultati et al. 2010). As incidental findings are per definition
unrelated to the patient’s complaints, the question to what
extent additional testing should be performed is part of both a
medical and ethical discussion (Sijmons et al. 2011). Further
research may burden the patient both mentally and physically,
and may bring considerable extra costs (Ding et al. 2011;
Stern 2012). To limit these aspects as much as possible, early
consultation of clinical experts is recommended.
Synopsis
Interpretation of diagnostic tests for rare diseases by clinical
experts is vital.
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